IL1B and neoplasm: On the other hand, the inhibition of NLRP3 inflammasome using MCC950 reduced LPS, ATP, PTX-mediated caspase-1 and IL-1β release, both in normal cells (p < 0.01 and p < 0.001, respectively) and tumor cells (p < 0.001 and p < 0.0001, respectively).